Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis

• N. Wu ^[1] ; F. Fu ^[1] ; L. Chen ^[1] ; Y. Lin ^[1] ; P. Yang ^[1] ; C.Wang ^[1]
  1. [1] Department of General Surgery, Affiliated Union Hospital of Fujian Medical University, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 4, 2020, págs. 474-485
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background The prognostic and clinical significance of single hormone receptor expression in breast cancer has not been clearly established. The goal of this study was to conduct a meta-analysis to compare the clinical outcomes of patients with ER+PR− tumours and ER−PR+ tumours to those of patients with ER+PR+ tumours.

    Methods A systematic review of the literature was conducted to identify studies that compared the clinical outcome of patients with ER+PR− tumours or ER−PR+ tumours with those of patients with ER+PR+ tumours. A total of 18 studies met the inclusion criteria and included 217,485 women. Standard methods for meta-analysis were used, including fixed-effect models.

    Results Patients with ER+PR− tumours or ER−PR+ tumours had significantly worse DFS (HR 1.60, 95% CI 1.44–1.77 and HR 2.27, 95% CI 1.67–3.09), BCSS (HR 1.43, 95% CI 1.33–1.53 and HR 1.82, 95% CI 1.68–1.98) and OS (HR 1.38, 95% CI 1.28–1.47 and HR 1.48, 95% CI 1.17–1.89) than those of patients with ER+PR+ tumours. In subgroup analyses, patients who had ER+PR− tumours experienced a higher risk of recurrence than patients with ER+PR+ tumours in the HER2− (HR 1.57, 95% CI 1.32–1.87), LN − (HR 2.07, 95% CI 1.44–2.86) and endocrine therapy (HR 1.65, 95% CI 1.45–1.89) subgroup. Patients who had HER2− and ER−PR+ tumours had an increased risk of recurrence compared with patients who had HER2− and ER+PR+ tumours (HR 3.10, 95% CI 1.92–5.10).

    Conclusions Among patients with hormone receptor-positive breast cancer, patients with either ER+PR− tumours or ER−PR+ tumours have a higher risk of recurrence and a shorter survival time than those with ER+PR+ tumours. Patients with both types of breast cancer need additional or better treatments.